Análisis de la efectividad del tratamiento neoadyuvante al añadir docetaxel secuencial a fluorouracilo, epirrubicina y ciclofosfamida en pacientes con cáncer de mama avanzado: resultados preliminares de respuesta tumoral-Reference-Cited by-同舟云学术

Análisis de la efectividad del tratamiento neoadyuvante al añadir docetaxel secuencial a fluorouracilo, epirrubicina y ciclofosfamida en pacientes con cáncer de mama avanzado: resultados preliminares de respuesta tumoral

Published:2015-01 Issue:1 Volume:14 Page:3-12
ISSN:1665-9201
Container-title:Gaceta Mexicana de Oncología
language:es
Short-container-title:Gaceta Mexicana de Oncología

Author:

Ramírez-Torres Nicolás,Moctezuma-Meza Christian,Asbun-Bojalil Juan,Valenzuela-Martínez Larissa Antonieta,Victoria-Ayala Rosalia,Ortiz-Rodríguez Kenia,Ayala-Anzures María Eugenia,Navarro-Muñoz Fidel,Castelazo-Rico Germán,Patlán-Pérez Rosa María,Tena-Alávez Gilberto,Vega Horacio Astudillo-de la

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Evidence-based use of neoadjuvanttaxane in operable and inoperable breast cáncer;Estevez;Clin Cancer Res.,2004

2. Primary systemic therapy of breast cancer;Sachelarie;The Oncologist .,2006

3. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update;Kaufmann;J Clin Oncol.,2006

4. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer;Chevallier;J Clin Oncol.,1995

5. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer;Nabholtz;J Clin Oncol.,1996

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of molecular classification by immunohistochemistry in advanced breast cancer treated with epirubicin and docetaxel: clinical, pathological, therapeutic and prognostic differences;Gaceta Mexicana de Oncolog�a;2019-04-09

2. Molecular subtypes in advanced breast cancer respond differently to neoadjuvant chemotherapy: assessment of complete pathologic response and prognosis;GAC MEX ONCOL;2018